vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $139.2M, roughly 1.4× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 2.2%, a 33.2% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 5.2%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $1.1M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -3.3%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
ADMA vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $200.5M |
| Net Profit | $49.4M | $4.5M |
| Gross Margin | 63.8% | 32.2% |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | 2.2% |
| Revenue YoY | 18.4% | 5.2% |
| Net Profit YoY | -55.9% | 421.4% |
| EPS (diluted) | $0.20 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $139.2M | $201.5M | ||
| Q3 25 | $134.2M | $216.0M | ||
| Q2 25 | $122.0M | $202.8M | ||
| Q1 25 | $114.8M | $190.5M | ||
| Q4 24 | $117.5M | $192.2M | ||
| Q3 24 | $119.8M | $210.3M | ||
| Q2 24 | $107.2M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $49.4M | $4.6M | ||
| Q3 25 | $36.4M | $8.6M | ||
| Q2 25 | $34.2M | $-73.6M | ||
| Q1 25 | $26.9M | $-1.4M | ||
| Q4 24 | $111.9M | $-500.0K | ||
| Q3 24 | $35.9M | $10.7M | ||
| Q2 24 | $32.1M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 63.8% | 31.5% | ||
| Q3 25 | 56.3% | 33.5% | ||
| Q2 25 | 55.1% | 31.6% | ||
| Q1 25 | 53.2% | 29.9% | ||
| Q4 24 | 53.9% | 32.1% | ||
| Q3 24 | 49.8% | 35.2% | ||
| Q2 24 | 53.6% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | 3.5% | ||
| Q3 25 | 38.0% | 7.3% | ||
| Q2 25 | 35.1% | -33.3% | ||
| Q1 25 | 30.4% | -0.2% | ||
| Q4 24 | 32.6% | -6.6% | ||
| Q3 24 | 33.1% | 6.9% | ||
| Q2 24 | 36.6% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 35.5% | 2.3% | ||
| Q3 25 | 27.1% | 4.0% | ||
| Q2 25 | 28.1% | -36.3% | ||
| Q1 25 | 23.4% | -0.7% | ||
| Q4 24 | 95.2% | -0.3% | ||
| Q3 24 | 30.0% | 5.1% | ||
| Q2 24 | 29.9% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.20 | $0.20 | ||
| Q3 25 | $0.15 | $0.48 | ||
| Q2 25 | $0.14 | $-4.00 | ||
| Q1 25 | $0.11 | $-0.08 | ||
| Q4 24 | $0.45 | $-0.04 | ||
| Q3 24 | $0.15 | $0.58 | ||
| Q2 24 | $0.13 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $195.8M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $1.2B |
| Total Assets | $624.2M | $1.4B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $87.6M | $197.0M | ||
| Q3 25 | $61.4M | $167.8M | ||
| Q2 25 | $90.3M | $157.2M | ||
| Q1 25 | $71.6M | $175.6M | ||
| Q4 24 | $103.1M | $159.8M | ||
| Q3 24 | $86.7M | $146.4M | ||
| Q2 24 | $88.2M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $477.3M | $1.2B | ||
| Q3 25 | $431.2M | $1.2B | ||
| Q2 25 | $398.3M | $1.2B | ||
| Q1 25 | $373.4M | $1.3B | ||
| Q4 24 | $349.0M | $1.3B | ||
| Q3 24 | $231.9M | $1.3B | ||
| Q2 24 | $188.3M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $624.2M | $1.4B | ||
| Q3 25 | $568.7M | $1.4B | ||
| Q2 25 | $558.4M | $1.5B | ||
| Q1 25 | $510.6M | $1.5B | ||
| Q4 24 | $488.7M | $1.5B | ||
| Q3 24 | $390.6M | $1.5B | ||
| Q2 24 | $376.4M | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $5.8M |
| Free Cash FlowOCF − Capex | $34.6M | $1.1M |
| FCF MarginFCF / Revenue | 24.8% | 0.5% |
| Capex IntensityCapex / Revenue | 0.8% | 2.3% |
| Cash ConversionOCF / Net Profit | 0.72× | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $35.6M | $46.9M | ||
| Q3 25 | $13.3M | $28.9M | ||
| Q2 25 | $21.1M | $13.7M | ||
| Q1 25 | $-19.7M | $11.7M | ||
| Q4 24 | $50.2M | $33.7M | ||
| Q3 24 | $25.0M | $42.4M | ||
| Q2 24 | $45.6M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $34.6M | $42.2M | ||
| Q3 25 | $-1.1M | $21.2M | ||
| Q2 25 | $18.7M | $5.6M | ||
| Q1 25 | $-24.4M | $2.1M | ||
| Q4 24 | $47.5M | $18.3M | ||
| Q3 24 | $24.0M | $25.2M | ||
| Q2 24 | $43.6M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 24.8% | 20.9% | ||
| Q3 25 | -0.8% | 9.8% | ||
| Q2 25 | 15.3% | 2.8% | ||
| Q1 25 | -21.2% | 1.1% | ||
| Q4 24 | 40.4% | 9.5% | ||
| Q3 24 | 20.0% | 12.0% | ||
| Q2 24 | 40.7% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.8% | 2.3% | ||
| Q3 25 | 10.7% | 3.6% | ||
| Q2 25 | 2.0% | 4.0% | ||
| Q1 25 | 4.1% | 5.0% | ||
| Q4 24 | 2.3% | 8.0% | ||
| Q3 24 | 0.9% | 8.2% | ||
| Q2 24 | 1.9% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 0.72× | 10.20× | ||
| Q3 25 | 0.36× | 3.36× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 3.96× | ||
| Q2 24 | 1.42× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
ROG
Segment breakdown not available.
